PRIMARY MEMBRANOUS NEPHROPATHY

This study tests a new drug, B007, against a standard treatment (cyclosporine) for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will join. The goal is to see if B007 …

This early-stage study tests a new drug given as a shot under the skin for people with a kidney condition called primary membranous nephropathy. The goal is to see if it is safe and how well it works. About 52 adults aged 18 to 75 will take part.

This study tests a new drug, SHR-2173, in 75 adults with primary membranous nephropathy, a kidney disease. The goal is to see if the drug is safe and can help control the disease by reducing protein in the urine. Participants will receive the drug and be monitored for side effect…

This study tests a new drug, felzartamab, for people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. The goal is to see if felzartamab can lower protein in urine and keep kidneys working better than the current drug,…

This study tests a new drug, budoprutug, in 45 adults with primary membranous nephropathy, a kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can help reduce protein in the urine, a sign of kidney damage. Participants will rec…

This study tests a new drug called WAL0921 in 96 adults with kidney diseases that cause protein in the urine, including diabetic kidney disease and rare conditions like FSGS. Participants receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks, then ar…

This study tests whether a new drug, povetacicept, works better than a standard treatment (calcineurin inhibitor) for people with primary membranous nephropathy, a kidney disease. About 176 adults will take part. The goal is to see if the new drug can help more patients achieve c…

This study tests whether adding finerenone to standard blood pressure medicines can better reduce protein in the urine of people with primary membranous nephropathy, a kidney disease. About 116 adults will be split into two groups: one gets the standard treatment alone, the other…

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check the drug's safety and how the body processes it. Researchers will also look for early signs that the drug mi…

This study compares a newer targeted drug, obinutuzumab, with a standard chemotherapy-based treatment (cyclophosphamide plus steroids) for people with a serious kidney condition called primary membranous nephropathy. About 144 adults with high protein in their urine will receive …

This study tests an experimental drug, ALXN1920, in 30 adults with primary membranous nephropathy (PMN) who are at high risk for their kidney disease getting worse. Participants will receive either the drug or a placebo, and researchers will measure changes in protein levels in u…

This study tests a new treatment called NKX019, which uses specially engineered immune cells (CAR NK cells) to target and calm overactive immune cells that attack the kidneys. It is for people with active lupus nephritis or primary membranous nephropathy who have not responded to…